Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | DHPS | P49366 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425920 | 0.82 | MAOB (0.59) | SRD5A2RAB9ANPC1 | |
| SCHEMBL2353757 | 0.79 | ALDH1A1 (0.58) | SRD5A2RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10946728 | 0.78 | SRD5A2 (0.83) | SRD5A2RAB9ANPC1SMN1; SMN2HSP90AA1 | |
| SCHEMBL1148445 | 0.78 | SRD5A2 (0.83) | SRD5A2RAB9ANPC1SMN1; SMN2HSP90AA1 | |
| SCHEMBL1897467 | 0.77 | MAPT (0.56) | SRD5A2RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL10468974 | 0.77 | ALOX5 (0.55) | RAB9ANPC1SMN1; SMN2HSP90AA1PKM | |
| SCHEMBL1074961 | 0.77 | ALDH1A1 (0.56) | SRD5A2RAB9ASMN1; SMN2ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL27713186 | 0.76 | SRD5A2 (0.79) | SRD5A2RAB9ANPC1SMN1; SMN2HSP90AA1 | |
| SCHEMBL371069 | 0.76 | TSHR (0.54) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL6424225 | 0.76 | SMN1; SMN2 (0.67) | SRD5A2RAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-110325512-A | The method for being used to prepare chiral pyrrolidine -2- base carbinol derivatives | 豪夫迈·罗氏有限公司 | 2019-10-11 | — | — | CN | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | SRD5A2 2337/4885RAB9A 719/4885NPC1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.